Sustained intracellular retention of dolastatin 10 causes its potent antimitotic activity

Molecular Pharmacology

Volumn 57, Issue 1, 2000, Pages 180-187

  Verdier Pinard, Pascal ^a   Kepler, John A ^b   Pettit, George R ^c   Hamel, Ernest ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b RTI INTERNATIONAL   (United States)

^c ARIZONA STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DOLASTATIN 10; VINBLASTINE;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BURKITT LYMPHOMA; CYTOTOXICITY; DRUG POTENCY; DRUG UPTAKE; HUMAN; HUMAN CELL; PRIORITY JOURNAL;

ANTINEOPLASTIC AGENTS; BIOLOGICAL TRANSPORT; BURKITT LYMPHOMA; CELL DIVISION; HUMANS; INHIBITORY CONCENTRATION 50; KINETICS; OLIGOPEPTIDES; TRITIUM; TUMOR CELLS, CULTURED; VINBLASTINE;

EID: 0033960022     PISSN: 0026895X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. Bagniewski PG, Reid JM, Pitot HC, Sloan JA and Ames MM (1997) Pharmacokinetics of dolastatin 10 in adult patients with solid tumors. Proc Am Assoc Cancer Res 38:221-222.
2. Bai R, Friedman SJ, Pettit GR and Hamel E (1992) Dolastatin 15, a potent antimitotic depsipeptide derived from Dolabella auricularia: Interaction with tubulin and effects on cellular microtubules. Biochem Pharmacol 43:2637-2645.
3. Bai R, Pettit GR and Hamel E (1990a) Binding of dolastatin 10 to tubulin at a distinct site for peptide antimitotic agents near the exchangeable nucleotide and vinca alkaloid sites. J Biol Chem 265:17141-17149.
4. Bai R, Pettit GR and Hamel E (1990b) Dolastatin 10, a powerful cytostatic peptide derived from a marine animal: Inhibition of tubulin polymerization mediated through the vinca alkaloid binding domain. Biochem Pharmacol 39:1941-1949.
5. Bai R, Schwartz RE, Kepler JA, Pettit GR and Hamel E (1996) Characterization of the interaction of cryptophycin 1 with tubulin: Binding in the Vinca domain, competitive inhibition of dolastatin 10 binding, and an unusual aggregation reaction. Cancer Res 56:4398-4406.
6. Bai R, Taylor GF, Schmidt JM, Williams MD, Kepler JA, Pettit GR and Hamel E (1995) Interaction of dolastatin 10 with tubulin: Induction of aggregation and binding and dissociation reactions. Mol Pharmacol 47:965-976.
7. Beckwith M, Urba WJ and Longo DL (1993) Growth inhibition of human lymphoma cell lines by the marine products, dolastatins 10 and 15. J Natl Cancer Inst 85:483-488.
8. 3H]-vincristine accumulation by L1210 mouse leukemic cells: Effect of P-glycoprotein overexpression. Gen Physiol Biophys 13:287-298.
9. Chen BD-M, Nakeff A and Valeriote F (1998) Cellular uptake of a novel cytotoxic agent, cryptophycin 52, by human THP-1 leukemia cells and H-125 lung tumor cells. Int J Cancer 77:869-873.
10. Cherney BW, Bhatia KG, Sgadari C, Gutierrez MI, Mostowski H, Pike SE, Gupta G, Magrath IT and Tosato G (1997) Role of the p53 tumor suppressor gene in the tumorigenicity of Burkitt's lymphoma cells. Cancer Res 57:2508-2515.
11. Dhamodharan R, Jordan MA, Thrower D, Wilson L and Wadsworth P (1995) Vinblastine suppresses dynamics of individual microtubules in living interphase cells. Mol Biol Cell 6:1215-1229.
12. El Hafny B, Cano N, Piciotti M, Regina A, Scherrmann J-M and Roux F (1997) Role of P-glycoprotein in colchicine and vinblastine cellular kinetics in an immortalized rat brain microvessel endothelial cell line. Biochem Pharmacol 53:1735-1742.
13. Ferguson PJ and Cass CE (1985) Differential cellular retention of vincristine and vinblastine by cultured human promyelocytic leukemia HL-60/Cl cells: The basis of differential cytotoxicity. Cancer Res 45:5480-5488.
14. Gottesman MM and Pastan I (1993) Biochemistry of multidrug resistance mediated by the multidrug transporter. Annu Rev Biochem 62:385-427.
15. Gout PW, Noble RL, Bruchovsky N and Beer CT (1984) Vinblastine and vincristine: Growth inhibitory effects correlate with their retention by cultured Nb 2 node lymphoma cells. Int J Cancer 34:245-248.
16. Hamel E and Lin CM (1984) Separation of active tubulin and microtubule-associated proteins by ultracentrifugation and isolation of a component causing the formation of microtubule bundles. Biochemistry 23:4173-4184.
17. Himes RH (1991) Interactions of the Catharanthus (Vinca) alkaloids with tubulin and microtubules. Pharmacol Ther 51:257-267.
18. Jordan MA, Thrower D and Wilson L (1991) Mechanism of inhibition of cell proliferation by Vinca alkaloids. Cancer Res 51:2212-2222.
19. Jordan MA and Wilson L (1990) Kinetic analysis of tubulin exchange at microtubule ends at low vinblastine concentrations. Biochemistry 29:2730-2739.
20. Kerksiek K, Mejillano MR, Schwartz RE, Georg GI and Himes RH (1995) Interaction of cryptophycin 1 with tubulin and microtubules. FEBS Lett 377:59-61.
21. Lengsfeld AM, Dietrich J and Schultze-Maurer B (1982) Accumulation and release of vinblastine and vincristine by HeLa cells: Light microscopic, cinematographic, and biochemical study. Cancer Res 42:3798-3805.
22. Magrath IT, Pizzo PA, Whang-Peng J, Douglass EC, Alabaster O, Gerber P, Freeman CB and Novikovs L (1980) Characterization of lymphoma-derived cell lines: comparison of cell lines positive and negative for Epstein-Barr virus nuclear antigen. I. Physical, cytogenetic, and growth characteristics. J Natl Cancer Inst 64:465-473.
23. Mickley LA, Lee SJ, Weng Z, Zhan Z, Alvarez M, Wilson W, Bates SE and Fojo T (1998) Genetic polymorphism in MDR-1: A tool for examining allelic expression in normal cells, unselected and drug-selected cell lines, and human tumors. Blood 91:1749-1756.
24. Monks A, Marquez VA, Mao DT and Cysyk RL (1985) Uptake of 2-β-D-ribofuranosylthiazole-4-carboxamide (tiazofurin) and analogues by the facilitated transport mechanism of erythrocytes. Cancer Lett 28:1-8.
25. Mooberry SL, Busquets L and Tien G (1997) Induction of apoptosis by cryptophycin 1, a new antimicrotubule agent. Int J Cancer 73:440-448.
26. Moore RE (1997) Presentation at the Fourth Anticancer Drug Discovery and Development Symposium; Aug 4-6, 1997; Annapolis, MD.
27. Panda D, DeLuca K, Williams D, Jordan MA and Wilson L (1998) Antiproliferative mechanism of action of cryptophycin-52: Kinetic stabilization of microtubule dynamics by high-affinity binding to microtubule ends. Proc Natl Acad Sci USA 98:9313-9318.
28. Pettit GR, Kamano Y, Herald CL, Tuinman AA, Boettner FE, Kizu H, Schmidt JM, Baczynskyj L, Tomer KB and Bontems RJ (1987) The isolation and structure of a remarkable marine animal antineoplastic constituent: Dolastatin 10. J Am Chem Soc 109:6883-6885.
29. Pettit GR, Singh SB, Hogan F, Lloyd-Williams P, Herald DL, Burkett DD and Clewlow PJ (1989) The absolute configuration and synthesis of natural (-)-dolastatin 10. J Am Chem Soc 111:5463-5465.
30. Pierre A, Perez V, Leonce S, Boutin JA, Saint-Dizier D, Hautefaye P, Lavielle G and Atassi G (1992) Relationship between the cellular accumulation and the cytotoxicity of S12363, a new Vinca alkaloid derivative. Cancer Chemother Pharmacol 29:367-374.
31. Rubin RW, Quillen M, Corcoran JJ, Ganapathi R and Krishan A (1982) Tubulin as a major cell surface protein in human lymphoid cells of leukemic origin. Cancer Res 42:1384-1389.
32. Safa AR, Hamel E and Felsted RL (1987) Photoaffinity labeling of tubulin subunits with a photoactive analogue of vinblastine. Biochemistry 26:97-102.
33. Singer WD, Hersh RT and Himes RH (1988) Effect of solution variables on the binding of vinblastine to tubulin. Biochem Pharmacol 37:2691-2696.
34. Singer WD and Himes RH (1992) Cellular uptake and tubulin binding properties of four vinca alkaloids. Biochem Pharmacol 43:545-551.
35. Smith CD and Zhang X (1996) Mechanism of action of cryptophycin: Interaction with the Vinca alkaloid domain of tubulin. J Biol Chem 271:6192-6198.
36. Thrower D, Jordan MA and Wilson L (1991) Quantitation of cellular tubulin in microtubules and tubulin pools by a competitive ELISA. J Immunol Methods 136:45-51.
37. Turner T, Jackson WH, Pettit GR, Wells A and Kraft AS (1998) Treatment of human prostate cancer cells with dolastatin 10, a peptide isolated from a marine shell-less mollusc. Prostate 34:175-181.
38. Van Belle SJ, De Smet MC, De Mey JE and Storme GA (1991) Cellular pharmacokinetics of vinblastine and other vinca alkaloids in MO4 cells. Anticancer Res 11:465-471.
39. Waud WR, Dykes DJ, Pettit GR and Plowman J (1993) Preclinical antitumor activity of dolastatin 10. Proc Am Assoc Cancer Res 34:383.
40. Wilson L and Jordan MA (1995) Microtubule dynamics: Taking aim at a moving target. Chem Biol 2:569-573.